Organogenesis Holdings Inc. (ORGO) 10-Year Financial Performance & Capital Metrics

ORGO • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryRegenerative Medicine

AboutOrganogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.Show more

Revenue $482M +11.3%
EBITDA $16M -56.2%
Net Income $861K -82.6%
EPS (Diluted) 0.01 -82.6%
Gross Margin 75.99% +0.8%
EBITDA Margin 3.27% -60.7%
Operating Margin -0.27% -109.2%
Net Margin 0.18% -84.4%
ROE 0.26% -85.7%
ROIC -0.33% -110.1%
Debt/Equity 0.11 -73.8%
Interest Coverage -0.83 -114.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 13.1%
✓Trading at only 1.4x book value

✗Weaknesses

✗Weak 3Y average ROE of 2.7%
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Dividend payout exceeds 100% of earnings
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y13.06%

3Y1.04%

TTM2.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-79.09%

TTM113.62%

EPS CAGR

10Y-

5Y-

3Y-78.98%

TTM-68.85%

ROCE

10Y Avg-0.24%

5Y Avg9.56%

3Y Avg3.02%

Latest-0.32%

Peer Comparison

Regenerative Medicine

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ORGOOrganogenesis Holdings Inc.	503.84M	3.97	610.77	11.29%	0.22%	0.26%	0.83%	0.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	193.45M	260.98M	338.3M	467.36M	450.89M	433.14M	482.04M
Revenue Growth %	-	-	-	0.35%	0.3%	0.38%	-0.04%	-0.04%	0.11%
Cost of Goods Sold+	208.7K	4.59M	68.81M	75.95M	87.32M	114.2M	105.02M	106.48M	115.74M
COGS % of Revenue	-	-	0.36%	0.29%	0.26%	0.24%	0.23%	0.25%	0.24%
Gross Profit+	-208.7K	-4.59M	124.64M	185.03M	250.98M	353.16M	345.87M	326.66M	366.3M
Gross Margin %	-	-	0.64%	0.71%	0.74%	0.76%	0.77%	0.75%	0.76%
Gross Profit Growth %	-	-21%	28.14%	0.48%	0.36%	0.41%	-0.02%	-0.06%	0.12%
Operating Expenses+	208.7K	4.59M	172.7M	214.89M	224.28M	280.94M	323.57M	314.13M	367.58M
OpEx % of Revenue	-	-	0.89%	0.82%	0.66%	0.6%	0.72%	0.73%	0.76%
Selling, General & Admin	208.7K	4.59M	161.96M	200.09M	204.19M	250.2M	283.81M	269.75M	294.51M
SG&A % of Revenue	-	-	0.84%	0.77%	0.6%	0.54%	0.63%	0.62%	0.61%
Research & Development	0	0	10.74M	14.8M	20.09M	30.74M	39.76M	44.38M	50.27M
R&D % of Revenue	-	-	0.06%	0.06%	0.06%	0.07%	0.09%	0.1%	0.1%
Other Operating Expenses	208.7K	0	162K	0	0	0	0	0	22.8M
Operating Income+	208.7K	-4.59M	-51.56M	-29.85M	26.7M	72.22M	22.3M	12.53M	-1.28M
Operating Margin %	-	-	-0.27%	-0.11%	0.08%	0.15%	0.05%	0.03%	-0%
Operating Income Growth %	-	-23%	-10.23%	0.42%	1.89%	1.7%	-0.69%	-0.44%	-1.1%
EBITDA+	-208.7K	1.04M	-44.58M	-20.03M	34.88M	88.89M	40.34M	35.97M	15.74M
EBITDA Margin %	-	-	-0.23%	-0.08%	0.1%	0.19%	0.09%	0.08%	0.03%
EBITDA Growth %	-	5.96%	-44.02%	0.55%	2.74%	1.55%	-0.55%	-0.11%	-0.56%
D&A (Non-Cash Add-back)	-417.4K	5.63M	6.98M	9.83M	8.18M	16.68M	18.03M	23.45M	17.03M
EBIT	-208.7K	-6.54M	-53.96M	-29.56M	29.04M	70.32M	22.29M	12.58M	-1.26M
Net Interest Income+	-5.47M	-8.01M	-10.79M	-9M	-11.28M	-7.24M	-2.01M	-2.19M	-1.54M
Interest Income	153K	0	64K	0	0	0	0	0	0
Interest Expense	5.63M	8.01M	10.85M	9M	11.28M	7.24M	2.01M	2.19M	1.54M
Other Income/Expense	8.57M	3.4M	-13.19M	-8.71M	-8.94M	-9.13M	-2.02M	-2.13M	-1.52M
Pretax Income+	-208.7K	-2.09M	-64.75M	-38.56M	17.76M	63.09M	20.28M	10.39M	-2.81M
Pretax Margin %	-	-	-0.33%	-0.15%	0.05%	0.13%	0.04%	0.02%	-0.01%
Income Tax+	-440.21K	-52.52K	84K	150K	530K	-31.12M	4.75M	5.45M	-3.67M
Effective Tax Rate %	1%	1%	1%	1%	0.97%	1.49%	0.77%	0.48%	-0.31%
Net Income+	-208.7K	-2.09M	-64.83M	-38.71M	17.23M	94.2M	15.53M	4.95M	861K
Net Margin %	-	-	-0.34%	-0.15%	0.05%	0.2%	0.03%	0.01%	0%
Net Income Growth %	-	-9.03%	-29.96%	0.4%	1.45%	4.47%	-0.84%	-0.68%	-0.83%
Net Income (Continuing)	-208.7K	-2.09M	-64.83M	-38.71M	17.23M	94.2M	15.53M	4.95M	861K
Discontinued Operations	0	-3.09M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.02	-0.03	-0.94	-0.44	0.15	0.70	0.12	0.04	0.01
EPS Growth %	-	-0.35%	-27.66%	0.53%	1.34%	3.67%	-0.83%	-0.69%	-0.83%
EPS (Basic)	-0.02	-0.03	-0.94	-0.44	0.16	0.73	0.12	0.04	0.01
Diluted Shares Outstanding	8.58M	63.88M	69.32M	92.84M	111.36M	133.66M	132.38M	132.75M	131.67M
Basic Shares Outstanding	8.58M	63.88M	68.97M	92.84M	107.74M	128.33M	130.07M	131.23M	131.67M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	2.09%

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.44M	294.44K	71.13M	125.6M	174.34M	226.98M	222.61M	225.04M	285.94M
Cash & Short-Term Investments	1.04M	125.89K	21.29M	60.17M	84.39M	113.93M	102.48M	104.34M	135.57M
Cash Only	1.04M	125.89K	21.29M	60.17M	84.39M	113.93M	102.48M	104.34M	135.57M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	34.08M	39.36M	56.8M	82.46M	89.45M	82M	109.86M
Days Sales Outstanding	-	-	64.3	55.05	61.29	64.4	72.41	69.1	83.19
Inventory	0	0	13.32M	22.92M	27.8M	25.02M	24.78M	28.25M	26.22M
Days Inventory Outstanding	-	-	70.66	110.14	116.2	79.97	86.13	96.85	82.68
Other Current Assets	0	0	353K	1.1M	584K	711K	5.1M	1.19M	5.67M
Total Non-Current Assets+	310M	312.5M	92.55M	95.09M	115.87M	216.28M	226.75M	234.98M	211.94M
Property, Plant & Equipment	0	0	39.62M	47.18M	55.79M	128.3M	145.66M	156.35M	126.24M
Fixed Asset Turnover	-	-	4.88x	5.53x	6.06x	3.64x	3.10x	2.77x	3.82x
Goodwill	0	0	25.54M	25.54M	28.77M	28.77M	28.77M	28.77M	28.77M
Intangible Assets	0	0	26.09M	20.8M	30.62M	25.67M	20.79M	15.87M	12.47M
Long-Term Investments	310M	312.5M	477K	0	0	0	0	15.87M	0
Other Non-Current Assets	0	0	579K	1.44M	670K	1.54M	1.52M	-9.88M	5M
Total Assets+	311.44M	312.79M	163.68M	220.69M	290.22M	443.26M	449.36M	460.02M	497.89M
Asset Turnover	-	-	1.18x	1.18x	1.17x	1.05x	1.00x	0.94x	0.97x
Asset Growth %	-	0%	-0.48%	0.35%	0.32%	0.53%	0.01%	0.02%	0.08%
Total Current Liabilities+	478.36K	3.93M	66.39M	59.89M	68.22M	82.7M	75.02M	80.51M	77.48M
Accounts Payable	0	19.05M	19.16M	28.39M	23.38M	29.34M	32.33M	30.72M	28.91M
Days Payables Outstanding	-	1.51K	101.66	136.43	97.73	93.77	112.36	105.32	91.17
Short-Term Debt	0	100K	2.54M	0	16.67M	2.66M	4.54M	5.49M	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0
Other Current Liabilities	0	-30.01M	22.22M	25.58M	21.58M	29.44M	9.33M	22.17M	25.29M
Current Ratio	3.00x	0.07x	1.07x	2.10x	2.56x	2.74x	2.97x	2.80x	3.69x
Quick Ratio	3.00x	0.07x	0.87x	1.71x	2.15x	2.44x	2.64x	2.44x	3.35x
Cash Conversion Cycle	-	-	33.3	28.76	79.76	50.6	46.18	60.63	74.7
Total Non-Current Liabilities+	10.85M	10.85M	50.25M	105.21M	80.19M	119.22M	108.67M	100.85M	35.09M
Long-Term Debt	0	0	39.06M	83.12M	53.04M	70.77M	66.23M	60.74M	0
Capital Lease Obligations	0	12.39M	10.15M	14.43M	11.44M	46.89M	41.31M	38.9M	34.2M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	10.85M	-1.54M	903K	7.66M	15.71M	1.56M	1.12M	1.21M	894K
Total Liabilities	11.33M	14.78M	116.64M	165.1M	148.41M	201.92M	183.69M	181.36M	112.57M
Total Debt+	0	17.86M	59.26M	100.61M	84.77M	132.3M	123.79M	119.35M	43.31M
Net Debt	-1.04M	17.73M	37.97M	40.43M	377K	18.37M	21.31M	15.01M	-92.26M
Debt / Equity	-	0.06x	1.26x	1.81x	0.60x	0.55x	0.47x	0.43x	0.11x
Debt / EBITDA	-	17.24x	-	-	2.43x	1.49x	3.07x	3.32x	2.75x
Net Debt / EBITDA	-	17.11x	-	-	0.01x	0.21x	0.53x	0.42x	-5.86x
Interest Coverage	0.04x	-0.57x	-4.75x	-3.32x	2.37x	9.98x	11.10x	5.72x	-0.83x
Total Equity+	300.11M	298.01M	47.04M	55.58M	141.81M	241.34M	265.67M	278.66M	385.32M
Equity Growth %	-	-0.01%	-0.84%	0.18%	1.55%	0.7%	0.1%	0.05%	0.38%
Book Value per Share	34.98	4.67	0.68	0.60	1.27	1.81	2.01	2.10	2.93
Total Shareholders' Equity	300.11M	298.01M	47.04M	55.58M	141.81M	241.34M	265.67M	278.66M	385.32M
Common Stock	295.11M	293.01M	9K	10K	13K	13K	13K	13K	13K
Retained Earnings	-233.86K	-2.33M	-130.24M	-171.01M	-155.03M	-60.83M	-45.3M	-40.97M	-40.11M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-295.11M	-293.01M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-562.23K	-586.6K	-60.74M	-33.53M	5.47M	61.98M	24.86M	30.92M	14.21M
Operating CF Margin %	-	-	-0.31%	-0.13%	0.02%	0.13%	0.06%	0.07%	0.03%
Operating CF Growth %	-	-0.04%	-102.54%	0.45%	1.16%	10.34%	-0.6%	0.24%	-0.54%
Net Income	-208.7K	-2.09M	-64.83M	-40.45M	17.23M	94.9M	15.53M	4.95M	861K
Depreciation & Amortization	7.32M	5.63M	6.98M	9.43M	8.18M	16.68M	10.73M	23.45M	17.03M
Stock-Based Compensation	473K	919K	1.07M	936K	1.66M	3.86M	6.55M	9M	10.58M
Deferred Taxes	0	0	186K	111K	112K	-31.98M	1.98M	2.01M	-10.72M
Other Non-Cash Items	-303.8M	-155.75K	18.25M	6.12M	6.03M	17.8M	24.15M	9.59M	45.35M
Working Capital Changes	-353.54K	1.51M	-22.4M	-9.67M	-27.76M	-39.29M	-34.08M	-18.07M	-48.89M
Change in Receivables	-6.56M	-7.01M	-7.11M	-4.69M	-17.57M	-30.23M	-8.77M	5.54M	-31.8M
Change in Inventory	-5.37M	-1.49M	-5M	-11.06M	-6.7M	-9.3M	-9.41M	6.58M	-6.2M
Change in Payables	0	0	-60K	4.7M	-4.1M	3.85M	3.26M	-108K	-2.37M
Cash from Investing+	-310M	-14.87M	-1.86M	-6.23M	-23.5M	-31.22M	-33.9M	-24.36M	-10.03M
Capital Expenditures	-1.36M	-2.43M	-1.86M	-6.23M	-17.68M	-31.22M	-33.9M	-24.36M	-10.03M
CapEx % of Revenue	-	-	0.01%	0.02%	0.05%	0.07%	0.08%	0.06%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-310M	-658K	1K	0	0	0	0	0	0
Cash from Financing+	311.48M	-327.58K	81.64M	78.73M	42.47M	-1.04M	-2.2M	-5.5M	27.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	-1.8M
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-5.2M	19.19M	80.72M	50.34M	-6.35M	-1.22M	814K	-332K	1.87M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.92M	-3.01M	-62.6M	-39.76M	-12.21M	30.76M	-9.04M	6.55M	4.18M
FCF Margin %	-	-	-0.32%	-0.15%	-0.04%	0.07%	-0.02%	0.02%	0.01%
FCF Growth %	-	-0.57%	-19.78%	0.36%	0.69%	3.52%	-1.29%	1.72%	-0.36%
FCF per Share	-0.22	-0.05	-0.90	-0.43	-0.11	0.23	-0.07	0.05	0.03
FCF Conversion (FCF/Net Income)	2.69x	0.28x	0.94x	0.87x	0.32x	0.66x	1.60x	6.25x	16.50x
Interest Paid	3.96M	6.08M	5.42M	8.15M	9.61M	5.79M	2.65M	5.44M	4.97M
Taxes Paid	29K	96K	8K	49K	61K	607K	1.2M	3.05M	6.96M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.07%	-0.7%	-37.58%	-75.44%	17.46%	49.17%	6.13%	1.82%	0.26%
Return on Invested Capital (ROIC)	0.05%	-1.12%	-19.3%	-24.74%	16.81%	26.95%	6.12%	3.24%	-0.33%
Gross Margin	-	-	64.43%	70.9%	74.19%	75.56%	76.71%	75.42%	75.99%
Net Margin	-	-	-33.51%	-14.83%	5.09%	20.16%	3.44%	1.14%	0.18%
Debt / Equity	-	0.06x	1.26x	1.81x	0.60x	0.55x	0.47x	0.43x	0.11x
Interest Coverage	0.04x	-0.57x	-4.75x	-3.32x	2.37x	9.98x	11.10x	5.72x	-0.83x
FCF Conversion	2.69x	0.28x	0.94x	0.87x	0.32x	0.66x	1.60x	6.25x	16.50x
Revenue Growth	-	-	-	34.91%	29.63%	38.15%	-3.52%	-3.94%	11.29%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Advanced Wound care	-	220.74M	294.62M	430.84M	422.23M	405.51M	453.64M
Advanced Wound care Growth	-	-	33.47%	46.23%	-2.00%	-3.96%	11.87%
Surgical and Sports Medicine	29.12M	40.24M	43.67M	37.22M	28.66M	27.63M	28.4M
Surgical and Sports Medicine Growth	-	38.19%	8.54%	-14.78%	-22.99%	-3.61%	2.82%
Advanced Wound Care	164.33M	-	-	-	-	-	-
Advanced Wound Care Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Organogenesis Holdings Inc. (ORGO) reported $465.0M in revenue for fiscal year 2024.

Organogenesis Holdings Inc. (ORGO) grew revenue by 11.3% over the past year. This is steady growth.

Yes, Organogenesis Holdings Inc. (ORGO) is profitable, generating $1.0M in net income for fiscal year 2024 (0.2% net margin).

Dividend & Returns

Yes, Organogenesis Holdings Inc. (ORGO) pays a dividend with a yield of 0.34%. This makes it attractive for income-focused investors.

Organogenesis Holdings Inc. (ORGO) has a return on equity (ROE) of 0.3%. This is below average, suggesting room for improvement.

Organogenesis Holdings Inc. (ORGO) had negative free cash flow of $51.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Organogenesis Holdings Inc. (ORGO) 10-Year Financial Performance & Capital Metrics

ORGO • • Industrial / General

HealthcareSpecialty & Generic PharmaMedical Devices & Drug DeliveryRegenerative Medicine

Revenue $482M +11.3%
EBITDA $16M -56.2%
Net Income $861K -82.6%
EPS (Diluted) 0.01 -82.6%
Gross Margin 75.99% +0.8%
EBITDA Margin 3.27% -60.7%
Operating Margin -0.27% -109.2%
Net Margin 0.18% -84.4%
ROE 0.26% -85.7%
ROIC -0.33% -110.1%
Debt/Equity 0.11 -73.8%
Interest Coverage -0.83 -114.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 13.1%
✓Trading at only 1.4x book value

✗Weaknesses

✗Weak 3Y average ROE of 2.7%
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Dividend payout exceeds 100% of earnings
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y13.06%

3Y1.04%

TTM2.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-79.09%

TTM113.62%

EPS CAGR

10Y-

5Y-

3Y-78.98%

TTM-68.85%

ROCE

10Y Avg-0.24%

5Y Avg9.56%

3Y Avg3.02%

Latest-0.32%

Peer Comparison

Regenerative Medicine

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ORGOOrganogenesis Holdings Inc.	503.84M	3.97	610.77	11.29%	0.22%	0.26%	0.83%	0.11

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	193.45M	260.98M	338.3M	467.36M	450.89M	433.14M	482.04M
Revenue Growth %	-	-	-	0.35%	0.3%	0.38%	-0.04%	-0.04%	0.11%
Cost of Goods Sold+	208.7K	4.59M	68.81M	75.95M	87.32M	114.2M	105.02M	106.48M	115.74M
COGS % of Revenue	-	-	0.36%	0.29%	0.26%	0.24%	0.23%	0.25%	0.24%
Gross Profit+	-208.7K	-4.59M	124.64M	185.03M	250.98M	353.16M	345.87M	326.66M	366.3M
Gross Margin %	-	-	0.64%	0.71%	0.74%	0.76%	0.77%	0.75%	0.76%
Gross Profit Growth %	-	-21%	28.14%	0.48%	0.36%	0.41%	-0.02%	-0.06%	0.12%
Operating Expenses+	208.7K	4.59M	172.7M	214.89M	224.28M	280.94M	323.57M	314.13M	367.58M
OpEx % of Revenue	-	-	0.89%	0.82%	0.66%	0.6%	0.72%	0.73%	0.76%
Selling, General & Admin	208.7K	4.59M	161.96M	200.09M	204.19M	250.2M	283.81M	269.75M	294.51M
SG&A % of Revenue	-	-	0.84%	0.77%	0.6%	0.54%	0.63%	0.62%	0.61%
Research & Development	0	0	10.74M	14.8M	20.09M	30.74M	39.76M	44.38M	50.27M
R&D % of Revenue	-	-	0.06%	0.06%	0.06%	0.07%	0.09%	0.1%	0.1%
Other Operating Expenses	208.7K	0	162K	0	0	0	0	0	22.8M
Operating Income+	208.7K	-4.59M	-51.56M	-29.85M	26.7M	72.22M	22.3M	12.53M	-1.28M
Operating Margin %	-	-	-0.27%	-0.11%	0.08%	0.15%	0.05%	0.03%	-0%
Operating Income Growth %	-	-23%	-10.23%	0.42%	1.89%	1.7%	-0.69%	-0.44%	-1.1%
EBITDA+	-208.7K	1.04M	-44.58M	-20.03M	34.88M	88.89M	40.34M	35.97M	15.74M
EBITDA Margin %	-	-	-0.23%	-0.08%	0.1%	0.19%	0.09%	0.08%	0.03%
EBITDA Growth %	-	5.96%	-44.02%	0.55%	2.74%	1.55%	-0.55%	-0.11%	-0.56%
D&A (Non-Cash Add-back)	-417.4K	5.63M	6.98M	9.83M	8.18M	16.68M	18.03M	23.45M	17.03M
EBIT	-208.7K	-6.54M	-53.96M	-29.56M	29.04M	70.32M	22.29M	12.58M	-1.26M
Net Interest Income+	-5.47M	-8.01M	-10.79M	-9M	-11.28M	-7.24M	-2.01M	-2.19M	-1.54M
Interest Income	153K	0	64K	0	0	0	0	0	0
Interest Expense	5.63M	8.01M	10.85M	9M	11.28M	7.24M	2.01M	2.19M	1.54M
Other Income/Expense	8.57M	3.4M	-13.19M	-8.71M	-8.94M	-9.13M	-2.02M	-2.13M	-1.52M
Pretax Income+	-208.7K	-2.09M	-64.75M	-38.56M	17.76M	63.09M	20.28M	10.39M	-2.81M
Pretax Margin %	-	-	-0.33%	-0.15%	0.05%	0.13%	0.04%	0.02%	-0.01%
Income Tax+	-440.21K	-52.52K	84K	150K	530K	-31.12M	4.75M	5.45M	-3.67M
Effective Tax Rate %	1%	1%	1%	1%	0.97%	1.49%	0.77%	0.48%	-0.31%
Net Income+	-208.7K	-2.09M	-64.83M	-38.71M	17.23M	94.2M	15.53M	4.95M	861K
Net Margin %	-	-	-0.34%	-0.15%	0.05%	0.2%	0.03%	0.01%	0%
Net Income Growth %	-	-9.03%	-29.96%	0.4%	1.45%	4.47%	-0.84%	-0.68%	-0.83%
Net Income (Continuing)	-208.7K	-2.09M	-64.83M	-38.71M	17.23M	94.2M	15.53M	4.95M	861K
Discontinued Operations	0	-3.09M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.02	-0.03	-0.94	-0.44	0.15	0.70	0.12	0.04	0.01
EPS Growth %	-	-0.35%	-27.66%	0.53%	1.34%	3.67%	-0.83%	-0.69%	-0.83%
EPS (Basic)	-0.02	-0.03	-0.94	-0.44	0.16	0.73	0.12	0.04	0.01
Diluted Shares Outstanding	8.58M	63.88M	69.32M	92.84M	111.36M	133.66M	132.38M	132.75M	131.67M
Basic Shares Outstanding	8.58M	63.88M	68.97M	92.84M	107.74M	128.33M	130.07M	131.23M	131.67M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	2.09%

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.44M	294.44K	71.13M	125.6M	174.34M	226.98M	222.61M	225.04M	285.94M
Cash & Short-Term Investments	1.04M	125.89K	21.29M	60.17M	84.39M	113.93M	102.48M	104.34M	135.57M
Cash Only	1.04M	125.89K	21.29M	60.17M	84.39M	113.93M	102.48M	104.34M	135.57M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	34.08M	39.36M	56.8M	82.46M	89.45M	82M	109.86M
Days Sales Outstanding	-	-	64.3	55.05	61.29	64.4	72.41	69.1	83.19
Inventory	0	0	13.32M	22.92M	27.8M	25.02M	24.78M	28.25M	26.22M
Days Inventory Outstanding	-	-	70.66	110.14	116.2	79.97	86.13	96.85	82.68
Other Current Assets	0	0	353K	1.1M	584K	711K	5.1M	1.19M	5.67M
Total Non-Current Assets+	310M	312.5M	92.55M	95.09M	115.87M	216.28M	226.75M	234.98M	211.94M
Property, Plant & Equipment	0	0	39.62M	47.18M	55.79M	128.3M	145.66M	156.35M	126.24M
Fixed Asset Turnover	-	-	4.88x	5.53x	6.06x	3.64x	3.10x	2.77x	3.82x
Goodwill	0	0	25.54M	25.54M	28.77M	28.77M	28.77M	28.77M	28.77M
Intangible Assets	0	0	26.09M	20.8M	30.62M	25.67M	20.79M	15.87M	12.47M
Long-Term Investments	310M	312.5M	477K	0	0	0	0	15.87M	0
Other Non-Current Assets	0	0	579K	1.44M	670K	1.54M	1.52M	-9.88M	5M
Total Assets+	311.44M	312.79M	163.68M	220.69M	290.22M	443.26M	449.36M	460.02M	497.89M
Asset Turnover	-	-	1.18x	1.18x	1.17x	1.05x	1.00x	0.94x	0.97x
Asset Growth %	-	0%	-0.48%	0.35%	0.32%	0.53%	0.01%	0.02%	0.08%
Total Current Liabilities+	478.36K	3.93M	66.39M	59.89M	68.22M	82.7M	75.02M	80.51M	77.48M
Accounts Payable	0	19.05M	19.16M	28.39M	23.38M	29.34M	32.33M	30.72M	28.91M
Days Payables Outstanding	-	1.51K	101.66	136.43	97.73	93.77	112.36	105.32	91.17
Short-Term Debt	0	100K	2.54M	0	16.67M	2.66M	4.54M	5.49M	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0
Other Current Liabilities	0	-30.01M	22.22M	25.58M	21.58M	29.44M	9.33M	22.17M	25.29M
Current Ratio	3.00x	0.07x	1.07x	2.10x	2.56x	2.74x	2.97x	2.80x	3.69x
Quick Ratio	3.00x	0.07x	0.87x	1.71x	2.15x	2.44x	2.64x	2.44x	3.35x
Cash Conversion Cycle	-	-	33.3	28.76	79.76	50.6	46.18	60.63	74.7
Total Non-Current Liabilities+	10.85M	10.85M	50.25M	105.21M	80.19M	119.22M	108.67M	100.85M	35.09M
Long-Term Debt	0	0	39.06M	83.12M	53.04M	70.77M	66.23M	60.74M	0
Capital Lease Obligations	0	12.39M	10.15M	14.43M	11.44M	46.89M	41.31M	38.9M	34.2M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	10.85M	-1.54M	903K	7.66M	15.71M	1.56M	1.12M	1.21M	894K
Total Liabilities	11.33M	14.78M	116.64M	165.1M	148.41M	201.92M	183.69M	181.36M	112.57M
Total Debt+	0	17.86M	59.26M	100.61M	84.77M	132.3M	123.79M	119.35M	43.31M
Net Debt	-1.04M	17.73M	37.97M	40.43M	377K	18.37M	21.31M	15.01M	-92.26M
Debt / Equity	-	0.06x	1.26x	1.81x	0.60x	0.55x	0.47x	0.43x	0.11x
Debt / EBITDA	-	17.24x	-	-	2.43x	1.49x	3.07x	3.32x	2.75x
Net Debt / EBITDA	-	17.11x	-	-	0.01x	0.21x	0.53x	0.42x	-5.86x
Interest Coverage	0.04x	-0.57x	-4.75x	-3.32x	2.37x	9.98x	11.10x	5.72x	-0.83x
Total Equity+	300.11M	298.01M	47.04M	55.58M	141.81M	241.34M	265.67M	278.66M	385.32M
Equity Growth %	-	-0.01%	-0.84%	0.18%	1.55%	0.7%	0.1%	0.05%	0.38%
Book Value per Share	34.98	4.67	0.68	0.60	1.27	1.81	2.01	2.10	2.93
Total Shareholders' Equity	300.11M	298.01M	47.04M	55.58M	141.81M	241.34M	265.67M	278.66M	385.32M
Common Stock	295.11M	293.01M	9K	10K	13K	13K	13K	13K	13K
Retained Earnings	-233.86K	-2.33M	-130.24M	-171.01M	-155.03M	-60.83M	-45.3M	-40.97M	-40.11M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-295.11M	-293.01M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-562.23K	-586.6K	-60.74M	-33.53M	5.47M	61.98M	24.86M	30.92M	14.21M
Operating CF Margin %	-	-	-0.31%	-0.13%	0.02%	0.13%	0.06%	0.07%	0.03%
Operating CF Growth %	-	-0.04%	-102.54%	0.45%	1.16%	10.34%	-0.6%	0.24%	-0.54%
Net Income	-208.7K	-2.09M	-64.83M	-40.45M	17.23M	94.9M	15.53M	4.95M	861K
Depreciation & Amortization	7.32M	5.63M	6.98M	9.43M	8.18M	16.68M	10.73M	23.45M	17.03M
Stock-Based Compensation	473K	919K	1.07M	936K	1.66M	3.86M	6.55M	9M	10.58M
Deferred Taxes	0	0	186K	111K	112K	-31.98M	1.98M	2.01M	-10.72M
Other Non-Cash Items	-303.8M	-155.75K	18.25M	6.12M	6.03M	17.8M	24.15M	9.59M	45.35M
Working Capital Changes	-353.54K	1.51M	-22.4M	-9.67M	-27.76M	-39.29M	-34.08M	-18.07M	-48.89M
Change in Receivables	-6.56M	-7.01M	-7.11M	-4.69M	-17.57M	-30.23M	-8.77M	5.54M	-31.8M
Change in Inventory	-5.37M	-1.49M	-5M	-11.06M	-6.7M	-9.3M	-9.41M	6.58M	-6.2M
Change in Payables	0	0	-60K	4.7M	-4.1M	3.85M	3.26M	-108K	-2.37M
Cash from Investing+	-310M	-14.87M	-1.86M	-6.23M	-23.5M	-31.22M	-33.9M	-24.36M	-10.03M
Capital Expenditures	-1.36M	-2.43M	-1.86M	-6.23M	-17.68M	-31.22M	-33.9M	-24.36M	-10.03M
CapEx % of Revenue	-	-	0.01%	0.02%	0.05%	0.07%	0.08%	0.06%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-310M	-658K	1K	0	0	0	0	0	0
Cash from Financing+	311.48M	-327.58K	81.64M	78.73M	42.47M	-1.04M	-2.2M	-5.5M	27.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	-1.8M
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-5.2M	19.19M	80.72M	50.34M	-6.35M	-1.22M	814K	-332K	1.87M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.92M	-3.01M	-62.6M	-39.76M	-12.21M	30.76M	-9.04M	6.55M	4.18M
FCF Margin %	-	-	-0.32%	-0.15%	-0.04%	0.07%	-0.02%	0.02%	0.01%
FCF Growth %	-	-0.57%	-19.78%	0.36%	0.69%	3.52%	-1.29%	1.72%	-0.36%
FCF per Share	-0.22	-0.05	-0.90	-0.43	-0.11	0.23	-0.07	0.05	0.03
FCF Conversion (FCF/Net Income)	2.69x	0.28x	0.94x	0.87x	0.32x	0.66x	1.60x	6.25x	16.50x
Interest Paid	3.96M	6.08M	5.42M	8.15M	9.61M	5.79M	2.65M	5.44M	4.97M
Taxes Paid	29K	96K	8K	49K	61K	607K	1.2M	3.05M	6.96M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.07%	-0.7%	-37.58%	-75.44%	17.46%	49.17%	6.13%	1.82%	0.26%
Return on Invested Capital (ROIC)	0.05%	-1.12%	-19.3%	-24.74%	16.81%	26.95%	6.12%	3.24%	-0.33%
Gross Margin	-	-	64.43%	70.9%	74.19%	75.56%	76.71%	75.42%	75.99%
Net Margin	-	-	-33.51%	-14.83%	5.09%	20.16%	3.44%	1.14%	0.18%
Debt / Equity	-	0.06x	1.26x	1.81x	0.60x	0.55x	0.47x	0.43x	0.11x
Interest Coverage	0.04x	-0.57x	-4.75x	-3.32x	2.37x	9.98x	11.10x	5.72x	-0.83x
FCF Conversion	2.69x	0.28x	0.94x	0.87x	0.32x	0.66x	1.60x	6.25x	16.50x
Revenue Growth	-	-	-	34.91%	29.63%	38.15%	-3.52%	-3.94%	11.29%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Advanced Wound care	-	220.74M	294.62M	430.84M	422.23M	405.51M	453.64M
Advanced Wound care Growth	-	-	33.47%	46.23%	-2.00%	-3.96%	11.87%
Surgical and Sports Medicine	29.12M	40.24M	43.67M	37.22M	28.66M	27.63M	28.4M
Surgical and Sports Medicine Growth	-	38.19%	8.54%	-14.78%	-22.99%	-3.61%	2.82%
Advanced Wound Care	164.33M	-	-	-	-	-	-
Advanced Wound Care Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Organogenesis Holdings Inc. (ORGO) reported $465.0M in revenue for fiscal year 2024.

Organogenesis Holdings Inc. (ORGO) grew revenue by 11.3% over the past year. This is steady growth.

Yes, Organogenesis Holdings Inc. (ORGO) is profitable, generating $1.0M in net income for fiscal year 2024 (0.2% net margin).

Dividend & Returns

Yes, Organogenesis Holdings Inc. (ORGO) pays a dividend with a yield of 0.34%. This makes it attractive for income-focused investors.

Organogenesis Holdings Inc. (ORGO) has a return on equity (ROE) of 0.3%. This is below average, suggesting room for improvement.

Organogenesis Holdings Inc. (ORGO) had negative free cash flow of $51.7M in fiscal year 2024, likely due to heavy capital investments.